Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Amortization (2021)

Neuphoria Therapeutics has reported Amortization over the past 1 years, most recently at $7.1 million for Q4 2021.

  • Quarterly Amortization changed N/A to $7.1 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $7.1 million through Dec 2021, changed N/A year-over-year, with the annual reading at $7.7 million for FY2021, N/A changed from the prior year.
  • Amortization was $7.1 million for Q4 2021 at Neuphoria Therapeutics, down from $7.7 million in the prior quarter.
  • Over five years, Amortization peaked at $7.7 million in Q2 2021 and troughed at $7.1 million in Q4 2021.